Search details
1.
Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases.
Int J Clin Oncol
; 25(2): 267-273, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31587134
2.
Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
BMC Cancer
; 19(1): 1051, 2019 Nov 06.
Article
in English
| MEDLINE | ID: mdl-31694572
3.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Lancet Oncol
; 19(1): 139-148, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29174310
4.
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
BMC Cancer
; 18(1): 1171, 2018 Nov 26.
Article
in English
| MEDLINE | ID: mdl-30477470
5.
Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
Oncologist
; 22(1): 61-69, 2017 01.
Article
in English
| MEDLINE | ID: mdl-28126915
6.
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.
World J Surg Oncol
; 15(1): 12, 2017 Jan 09.
Article
in English
| MEDLINE | ID: mdl-28069039
7.
Multiple primary malignancies involving lung cancer.
BMC Cancer
; 15: 696, 2015 Oct 14.
Article
in English
| MEDLINE | ID: mdl-26466785
8.
Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients.
Support Care Cancer
; 23(3): 635-41, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25155313
9.
Lung cancer treatment disparities in China: a question in need of an answer.
Oncologist
; 19(10): 1084-90, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25223463
10.
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
BMC Cancer
; 14: 684, 2014 Sep 20.
Article
in English
| MEDLINE | ID: mdl-25239521
11.
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Chin J Cancer
; 33(7): 346-50, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24823994
12.
Comparison of three mathematical prediction models in patients with a solitary pulmonary nodule.
Chin J Cancer Res
; 26(6): 647-52, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25561761
13.
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study.
Ther Adv Med Oncol
; 16: 17588359241229435, 2024.
Article
in English
| MEDLINE | ID: mdl-38333112
14.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Sci Bull (Beijing)
; 69(4): 535-543, 2024 Feb 26.
Article
in English
| MEDLINE | ID: mdl-38185589
15.
Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study.
Ann Nucl Med
; 38(3): 188-198, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38145431
16.
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).
Clin Lung Cancer
; 25(1): e1-e4, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37880076
17.
KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
Ann Surg Oncol
; 20(4): 1381-8, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23208128
18.
Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
Cancer Med
; 12(1): 396-406, 2023 01.
Article
in English
| MEDLINE | ID: mdl-35702826
19.
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Lung Cancer
; 175: 68-78, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36473332
20.
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.
J Immunother Cancer
; 11(7)2023 07.
Article
in English
| MEDLINE | ID: mdl-37463790